Neuronal bioenergetics and acute mitochondrial dysfunction: A clue to understanding the central nervous system side effects of efavirenz

Journal of Infectious Diseases

Volumn 210, Issue 9, 2014, Pages 1385-1395

  Funes, Haryes A ^a,c   Apostolova, Nadezda ^d,e   Alegre, Fernando ^a,c   Blas Garcia, Ana ^a,c   Alvarez, Angeles ^a,b,d   Marti Cabrera, Miguel ^a,d   Esplugues, Juan V ^a,c,d  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e UNIVERSITAT JAUME I   (Spain)

Author keywords

Central nervous system; Efavirenz; HIV; HIV associated neurocognitive disorders; Mitochondria; Neurotoxicity; Nitric oxide

Indexed keywords

ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; EFAVIRENZ; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LACTIC ACID; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; BENZOXAZINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANIMAL CELL; ARTICLE; ASTROCYTE; BIOENERGY; CELL DEGENERATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CENTRAL NERVOUS SYSTEM DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVATION; FLUORESCENCE MICROSCOPY; GLIA CELL; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; NERVE CELL CULTURE; NERVOUS SYSTEM INFLAMMATION; NEUROBLASTOMA CELL; NEUROTOXICITY; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN ISOLATION; RAT; WESTERN BLOTTING; ANIMAL; CELL RESPIRATION; DOSE RESPONSE; DRUG EFFECTS; ENERGY METABOLISM; GLIA; METABOLISM; MITOCHONDRION; NERVE CELL; TUMOR CELL LINE; WISTAR RAT;

ANIMALS; ASTROCYTES; BENZOXAZINES; CELL LINE, TUMOR; CELL RESPIRATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENERGY METABOLISM; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; NEUROGLIA; NEURONS; OXYGEN CONSUMPTION; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE INHIBITORS; SUPEROXIDES;

EID: 84922066922     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu273     Document Type: Article

References (39)

1. Bolaños JP, Almeida A, Moncada S. Glycolysis: a bioenergetic or a survival pathway? Trends Biochem Sci 2010; 35:145-9.
2. Almeida A, Moncada S, Bolaños JP. Nitric oxide switches on glycolysis through the AMP protein kinase and 6-phosphofructo-2-kinase pathway. Nat Cell Biol 2004; 6:45-51.
3. Saha RN, Pahan K. Differential regulation of Mn-superoxide dismutase in neurons and astroglia by HIV-1 gp120: Implications for HIV-associated dementia. Free Radic Biol Med 2007; 42:1866-78.
4. Fumaz CR, Munoz-Moreno JA, Molto J, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr 2005; 38:560-5.
5. Cavalcante GI, Capistrano VL, Cavalcante FS, et al. Implications of efavirenz for neuropsychiatry: a review. Int J Neurosci 2010; 120:739-45.
6. Ciccarelli N, Fabbiani M, Di Giambenedetto S, et al. Efavirenz associated with neurocognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 2011; 76:1403-9.
7. Streck EL, Ferreira GK, Scaini G, et al. Non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine inhibit cytochrome C oxidase in mouse brain regions. Neurochem Res 2011; 36:962-6.
8. Blas-García A, Apostolova N, Ballesteros D, et al. Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology 2010; 52:115-25.
9. Apostolova N, Blas-García A, Esplugues JV. Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-ã inhibition. Trends Pharmacol Sci 2011; 32:715-25.
10. Kaul M. HIV-1 associated dementia: update on pathological mechanisms and therapeutic approaches. Curr Opin Neurol 2009; 22:315-20.
11. Almeida A, Almeida J, Bolaños JP, Moncada S. Different responses of astrocytes and neurons to nitric oxide: the role of glycolytically generated ATP in astrocyte protection. Proc Natl Acad Sci U S A 2001; 98:15294-9.
12. Sánchez S, Jiménez C, Carrera AC, Diaz-Nido J, Avila J, Wandosell F. A cAMP activated pathway, including PKA and PI3K, regulates neuronal differentiation. Neurochem Int 2004; 44:231-42.
13. Almeida A, Medina JM. A rapid method for the isolation of metabolically active mitochondria from rat neurons and astrocytes in primary culture. Brain Res Brain Res Protoc 1998; 2:209-14.
14. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007; 8:774-85.
15. Goldstein S, Russo A, Samuni A. Reactions of PTIO and carboxy-PTIO with ∗NO, ∗NO2, and O2-∗. J Biol Chem 2003; 278:50949-55.
16. Wiesinger H, Hamprecht B, Dringen R. Metabolic pathways for glucose in astrocytes. Glia 1997; 21:22-34.
17. Bolaños JP, Almeida A. Modulation of astroglial energy metabolism by nitric oxide. Antioxid Redox Signal 2006; 8:955-65.
18. Erecińska M, Deas J, Silver IA. The effect of pH on glycolysis and phosphofructokinase activity in cultured cells and synaptosomes. J Neurochem 1995; 65:2765-72.
19. Moncada S, Erusalimsky JD. Does nitric oxide modulate mitochondrial energy generation and apoptosis? Nat Rev Mol Cell Biol 2002; 3:214-20.
20. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15:71-5.
21. Gutiérrez-Valencia A, Viciana P, Palacios R, et al. Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial. Ann Intern Med 2009; 151:149-56.
22. Gutiérrez F, Navarro A, Padilla S, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 2005; 41:1648-53.
23. Gounden V, van Niekerk C, Snyman T, George JA. Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res Ther 2010; 7:32.
24. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341:1865-73.
25. Taylor S, Reynolds H, Sabin CA, et al. Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men. AIDS 2001; 15:2051-3.
26. Burger D, van der Heiden I, la Porte C, et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol 2006; 61:148-54.
27. Carr DF, la Porte CJ, Pirmohamed M, Owen A, Cortes CP. Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. J Antimicrob Chemother 2010; 65:1889-93.
28. Avery LB, Sacktor N, McArthur JC, Hendrix CW. Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration. Antimicrob Agents Chemother 2013; 57:1409-14.
29. Streck EL, Scaini G, Rezin GT, Moreira J, Fochesato CM, Romao PR. Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity. Metab Brain Dis 2008; 23:485-92.
30. Brandmann M, Tulpule K, Schmidt MM, Dringen R. The antiretroviral protease inhibitors indinavir and nelfinavir stimulate Mrp1-mediated GSH export from cultured brain astrocytes. J Neurochem 2012; 120:78-92.
31. Apostolova N, Gomez-Sucerquia LJ, Gortat A, Blas-Garcia A, Esplugues JV. Compromising mitochondrial function with the antiretroviral drug efavirenz induces cell survival-promoting autophagy. Hepatology 2011; 54:1009-19.
32. McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neuroneurocognitive disorders: Mind the gap. Ann Neurol 2010; 67:699-714.
33. Peyriere H, Mauboussin JM, Rouanet I, Fabre J, Reynes J, Hillaire-Buys D. Management of sudden psychiatric disorders related to efavirenz. AIDS 2001; 15:1323-4.
34. Lochet P, Peyrière H, Lotthé A, Mauboussin JM, Delmas B, Reynes J. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med 2003; 4:62-6.
35. Esplugues JV. NO as a signalling molecule in the nervous system. Br J Pharmacol 2002; 135:1079-95.
36. Li W, Malpica-Llanos TM, Gundry R, et al. Nitrosative stress with HIV dementia causes decreased L-prostaglandin D synthase activity. Neurology 2008; 70:1753-62.
37. Walsh KA, Megyesi JF, Wilson JX, Crukley J, Laubach VE, Hammond RR. Antioxidant protection from HIV-1 gp120-induced neuroglial toxicity. J Neuroinflammation 2004; 1:8.
38. Li W, Galey D, Mattson MP, Nath A. Molecular and cellular mechanisms of neuronal cell death in HIV dementia. Neurotox Res 2005; 8:119-34.
39. Davidson DC, Schifitto G, Maggirwar SB. Valproic acid inhibits the release of soluble CD40L induced by non-nucleoside reverse transcriptase inhibitors in human immunodeficiency virus infected individuals. PLoS One 2013; 8:e59950.